Tianda Pharmaceuticals Balance Sheet

Financials in millions HKD. Fiscal year is January - December.

Millions HKD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Mar '22 Mar 31, 2022
Cash & Equivalents	64.81	85.69	162.44	340.28	334
Short-Term Investments	6.6	6.14	8.43	21.73	3.31
Trading Asset Securities	-	-	-	3.17	14.58
Cash & Short-Term Investments	71.41	91.83	170.87	365.17	351.9
Cash Growth	-22.24%	-46.26%	-53.21%	3.77%	47.88%
Accounts Receivable	76.48	77.42	104.8	138.75	141.74
Other Receivables	2.84	3.97	1.57	4.07	3.15
Receivables	79.32	81.39	106.38	142.82	144.89
Inventory	44.69	40.21	65.15	48.19	74.89
Prepaid Expenses	2.24	2.45	1.81	1.99	5.76
Total Current Assets	197.66	215.88	344.21	558.17	577.45
Property, Plant & Equipment	384.66	386.09	412.74	400.51	433.09
Long-Term Investments	-	-	9.22	0.74	1.77
Goodwill	79.89	90.39	95.23	95.95	106.21
Other Intangible Assets	27.22	27.21	1.31	1.75	15.51
Long-Term Deferred Charges	41.52	33.32	19.36	4.37	6.43
Other Long-Term Assets	16.87	12.14	35.22	26.97	23.7
Total Assets	747.83	765.02	917.29	1,088	1,164
Accounts Payable	93.96	77.82	117.99	80.73	110.11
Accrued Expenses	34.92	29.37	64.31	71.19	63.99
Short-Term Debt	11.13	-	-	-	-
Current Portion of Long-Term Debt	71.2	122.07	96.49	64.67	57.26
Current Portion of Leases	4.35	2.19	5.68	5.63	4.6
Current Income Taxes Payable	0.43	0.75	3.74	3.72	4.24
Current Unearned Revenue	9.12	8.43	13.71	111.73	14.08
Other Current Liabilities	13.21	10.36	11.38	24.76	17.37
Total Current Liabilities	238.32	251	313.31	362.43	271.66
Long-Term Debt	41.92	-	8.36	61.97	90.63
Long-Term Leases	4.07	3.18	3.07	8.77	7.94
Long-Term Unearned Revenue	0.78	-	-	0.09	0.19
Long-Term Deferred Tax Liabilities	6.37	5.18	0.61	0.96	4.65
Total Liabilities	291.46	259.36	325.35	434.23	375.08
Common Stock	215	215	215	215	215
Additional Paid-In Capital	359.07	359.07	364.66	364.66	364.66
Retained Earnings	-32.95	37.05	98.42	128.17	186.77
Comprehensive Income & Other	-84.48	-105.29	-86.02	-80	-9.68
Total Common Equity	456.64	505.84	592.07	627.83	756.75
Minority Interest	-0.28	-0.17	-0.13	26.41	32.32
Shareholders' Equity	456.36	505.67	591.94	654.24	789.08
Total Liabilities & Equity	747.83	765.02	917.29	1,088	1,164
Total Debt	132.66	127.45	113.6	141.05	160.43
Net Cash (Debt)	-61.25	-35.61	57.28	224.12	191.47
Net Cash Growth	-	-	-74.44%	17.06%	107.15%
Net Cash Per Share	-0.03	-0.02	0.03	0.10	0.09
Filing Date Shares Outstanding	2,150	2,150	2,150	2,150	2,150
Total Common Shares Outstanding	2,150	2,150	2,150	2,150	2,150
Working Capital	-40.67	-35.12	30.9	195.75	305.79
Book Value Per Share	0.21	0.24	0.28	0.29	0.35
Tangible Book Value	349.54	388.24	495.53	530.13	635.03
Tangible Book Value Per Share	0.16	0.18	0.23	0.25	0.30
Buildings	253.23	242.08	228.71	229.42	249.16
Machinery	231.26	214.64	212.46	179.2	184.23
Construction In Progress	27.72	25.34	40.39	28.98	23.69
Leasehold Improvements	5.29	5.72	4.71	4.02	4.17